Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irinotecan Liposome vs Capecitabine in Adjuvant Biliary Tract Carcinoma
NCT06699459Phase 2Not yet recruiting
- Sponsor
- Sir Run-Run Shaw Hospital
- Start
- Nov 2024
- Primary completion
- Nov 2026
- Modality
- Lipid-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of irinotecan liposome injection in biliary tract carcinoma (BTC), sponsored by Sir Run-Run Shaw Hospital. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
irinotecan liposome injection
03
Conditions
biliary tract carcinoma (BTC)
Beyond the preview
Go deeper on NCT06699459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06699459.